Immunotherapy combined with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 expression levels.

Cejemly (sugemalimab) - CStone Pharma

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Kaitanni (cadonilimab) - Akesobio

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42092825

Chengcheng Qu; Kalima Muhetaer; Leiyu Cao; Li Zhang; Longhai Chen; Muhetaibaier Hairoula; Wen Yi; Xiaoli Ma; Yan Gao; Yu Wei

May 7, 2026